ImmunityBio GAAP EPS of -$0.07 beats by $0.04, revenue of $32.06M beats by $0.18M

* ImmunityBio press release [https://seekingalpha.com/pr/20293555-driven-by-strong-demand-immunitybio-reports-467-percent-year-to-date-unit-growth-and-75] (IBRX [https://seekingalpha.com/symbol/IBRX]): Q3 GAAP EPS of -$0.07 beats by $0.04.
* Revenue of $32.06M (+424.7% Y/Y) beats by $0.18M.
* Cash Position: $257.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, up from $153.7 million as of June 30, 2025.

MORE ON IMMUNITYBIO

* ImmunityBio: A Small Bet Is Warranted [https://seekingalpha.com/article/4827740-immunitybio-small-bet-warranted]
* ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking [https://seekingalpha.com/article/4822139-immunitybio-still-too-early-to-judge-anktiva-although-clock-is-ticking]
* ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma [https://seekingalpha.com/news/4489223-immunitybio-rises-data-nk-cell-therapy-device-combo-glioblastoma]
* ImmunityBio higher after early-stage trial results for cell therapy in lymphoma [https://seekingalpha.com/news/4484730-immunitybio-up-trial-data-cell-therapy]
* Seeking Alpha’s Quant Rating on ImmunityBio [https://seekingalpha.com/symbol/IBRX/ratings/quant-ratings]